Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Erwin

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Diagnostic Microbiology and Infectious Disease|February 17, 1999
Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study GroupS A Marshall, R N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|October 1, 1994
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study GroupR N Jones, H S Sader, M E Erwin
Diagnostic Microbiology and Infectious Disease|June 4, 1999
Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study GroupR N Jones, S A Marshall, M E Erwin
Diagnostic Microbiology and Infectious Disease|March 26, 1999
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelinesD M Johnson, R N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|March 1, 1996
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinonesR N Jones, D M Johnson, M E Erwin
Antimicrobial Agents and Chemotherapy|February 1, 1997
In vitro activity and spectrum of LY333328, a novel glycopeptide derivativeR N Jones, M S Barrett, M E Erwin
Diagnostic Microbiology and Infectious Disease|February 1, 1995
Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strainsR N Jones, M E Erwin, S C Anderson
Journal of Clinical Microbiology|September 1, 1993
Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeaeM S Barrett, R N Jones, M E Erwin
The Journal of Antimicrobial Chemotherapy|July 1, 1996
Critical appraisal of E test for the detection of fluoroquinolone resistanceR N Jones, M E Erwin, J L Croco
Journal of Clinical Microbiology|April 1, 1992
Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolatesR N Jones, M E Erwin, B B Gooding
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Diagnostic Microbiology and Infectious Disease|February 17, 1999
Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study GroupS A Marshall, R N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|October 1, 1994
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study GroupR N Jones, H S Sader, M E Erwin
Diagnostic Microbiology and Infectious Disease|June 4, 1999
Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study GroupR N Jones, S A Marshall, M E Erwin
Diagnostic Microbiology and Infectious Disease|March 26, 1999
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelinesD M Johnson, R N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|March 1, 1996
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinonesR N Jones, D M Johnson, M E Erwin
Antimicrobial Agents and Chemotherapy|February 1, 1997
In vitro activity and spectrum of LY333328, a novel glycopeptide derivativeR N Jones, M S Barrett, M E Erwin
Diagnostic Microbiology and Infectious Disease|February 1, 1995
Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strainsR N Jones, M E Erwin, S C Anderson
Journal of Clinical Microbiology|September 1, 1993
Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeaeM S Barrett, R N Jones, M E Erwin
The Journal of Antimicrobial Chemotherapy|July 1, 1996
Critical appraisal of E test for the detection of fluoroquinolone resistanceR N Jones, M E Erwin, J L Croco
Journal of Clinical Microbiology|April 1, 1992
Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolatesR N Jones, M E Erwin, B B Gooding
Pageof 9